Cover Image
市場調查報告書

偏頭痛治療藥的全球市場 (2016∼2020年)

Global Migraine Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 324100
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
偏頭痛治療藥的全球市場 (2016∼2020年) Global Migraine Drugs Market 2016-2020
出版日期: 2016年05月02日 內容資訊: 英文 63 Pages
簡介

偏頭痛,特徵為沉重的頭痛和噁心、嘔吐感,對光、聲音的極度的敏感性等症狀重複來襲。由於體內的荷爾蒙水平變化的影響,女性有比男性容易發病的傾向。主要的治療藥,有抗發炎止痛藥和抗偏頭痛藥,止吐,Triptan藥物等。全球偏頭痛治療藥市場2016∼2020年的年複合成長率 (CAGR) 預計達到4.56%。

本報告提供全球的偏頭痛治療藥市場相關分析,市場概要和結構,市場規模趨勢(今後5年的預測值),開發中產品的各資訊,各治療等級、各地區的詳細趨勢,推動、阻礙市場要素與其影響力,主要企業簡介,今後的市場機會等調查、考察。

第1章 摘要整理

  • 分析結果的概要

第2章 分析範圍

  • 分析概要
  • 大供應商的主要產品

第3章 市場分析技術

  • 分析方法
  • 經濟指標

第4章 簡介

  • 市場趨勢的概要

第5章 疾病概要

  • 種類
  • 病因
  • 疾病管理
  • 病理生理學
  • 經濟負擔

第6章 開發中產品分析

  • Semprana
  • Rizaport
  • sumaTriptan
  • DFN-11
  • Lasmiditan
  • SUD001
  • AMG 334
  • DFN-02

第7章 市場環境

  • 市場概要
  • 市場規模與其預測
  • 波特的五力分析

第8章 治療方法的各種類的市場區隔

  • 預防的治療
  • 早期治療

第9章 各治療等級的市場區隔

  • Triptan
  • 麥角生物鹼
  • 其他

第10章 地區區分

  • 全球偏頭痛治療藥:各地區的詳細趨勢 (今後6年份)
  • 南北美洲市場
  • 歐洲、中東、非洲各國 (EMEA) 市場
  • 亞太地區市場

第11章 推動市場要素

  • 偏頭痛與其治療選擇相關認知度的上升
  • 開發平台候補藥的臨時認證
  • 巨大的未滿足需求
  • 偏頭痛的患病人數的增加

第12章 推動因素的影響力

第13章 市場課題

  • 缺乏恰當的診斷方法
  • 藥物的副作用
  • 替代療法廣受歡迎
  • 學名藥的普及

第14章 推動因素、課題的影響力

第15章 市場趨勢

  • 抗偏頭痛產品、頭帶
  • 研究開發 (R&D) 投資的增額
  • 新產品的開發
  • 策略性的產業聯盟

第16章 供應商環境

  • 競爭方案
  • Allergan
  • Endo International
  • GlaxoSmithKline
  • Impax
  • Pfizer
  • 其他卓越供應商

第17章 附錄

  • 簡稱集

第18章 關於Technavio

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR9324

About Migraines

A migraine is characterized by repeated attacks of a severe headache, nausea, vomiting, and extreme sensitivity to light and sound. Women are more prone to the disease compared to men owing to the fluctuating levels of hormones in their bodies. Therapeutic agents such as anti-inflammatory painkillers, antimigraine drugs, antisickness medicines, and triptans are used for the treatment of the disease.

Technavio's analysts forecast the global migraine drugs market to grow at a CAGR of 4.56% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global migraine drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that will be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Migraine Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Allergan
  • Endo International
  • GlaxoSmithKline
  • Impax
  • Pfizer

Other Prominent Vendors

  • Abbott
  • Aegis Therapeutics
  • Aeriel BioPharma
  • Alder Biopharmaceuticals
  • Amgen
  • Astellas
  • AstraZeneca
  • Bayer
  • CoLucid
  • Dr. Reddy's Laboratories
  • Eisai
  • Eli Lilly
  • Ethypharm
  • IntelGenx
  • Johnson & Johnson
  • Klaria
  • Kowa Pharmaceuticals America
  • Luitpold Pharmaceuticals
  • Meda
  • Merck
  • OptiNose
  • Pfizer
  • Pozen
  • Raptor
  • RedHill
  • SUDA
  • Teva
  • TG Therapeutics
  • NValeant
  • Winston Pharmaceuticals
  • Zogenix

Market driver

  • Growing awareness about migraine and its treatment options
  • For a full, detailed list, view our report

Market challenge

  • Lack of proper diagnosis
  • For a full, detailed list, view our report

Market trend

  • Antimigraine devices and headbands
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Types
  • Cause
  • Management
  • Epidemiology
  • Economic burden
  • PART 06: Pipeline analysis
  • Semprana
  • Rizaport
  • Sumatriptan
  • DFN-11
  • Lasmiditan
  • SUD001
  • AMG 334
  • DFN-02

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by type of treatment

  • Preventative
  • Abortive

PART 09: Market segmentation by therapeutic class

  • Triptans
  • Ergot alkaloids
  • Other

PART 10: Geographical segmentation

  • Global migraine drugs market by geographical segmentation 2015-2020
  • Migraine drugs market in Americas
  • Migraine drugs market in EMEA
  • Migraine drugs market in APAC

PART 11: Market drivers

  • Growing awareness about migraine and its treatment options
  • Tentative approval of pipeline candidates
  • High unmet needs
  • Increased prevalence of migraines

PART 12: Impact of drivers

PART 13: Market challenges

  • Lack of proper diagnosis
  • Adverse effects of drugs
  • Increased preference for alternative therapies
  • Generic penetration

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Antimigraine devices and headbands
  • Increase in R&D
  • Novel product innovations
  • Strategic alliances

PART 16: Vendor landscape

  • Competitive scenario
  • Allergan
  • Endo International
  • GlaxoSmithKline
  • Impax
  • Pfizer
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Percentage of migraine sufferers worldwide by gender
  • Exhibit 03: Global migraine drugs market: Pipeline portfolio
  • Exhibit 04: Global migraine drugs market 2015-2020 ($ billions)
  • Exhibit 05: Five forces analysis
  • Exhibit 06: Preventative medications based on efficacy of drugs
  • Exhibit 07: Medications used based on severity of migraines
  • Exhibit 08: Percentage share of preventative and abortive migraine medications in US 2015
  • Exhibit 09: Segmentation of global migraine drugs market by therapeutic class 2015
  • Exhibit 10: Market share of triptans by ROA 2015
  • Exhibit 11: Global migraine drugs market by geography 2015
  • Exhibit 12: Global migraine drugs market by geography 2015-2020 ($ millions)
  • Exhibit 13: Migraine drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 14: Migraine drugs market in EMEA 2015-2020 ($ millions)
  • Exhibit 15: Migraine drugs market in APAC 2015-2020 ($ millions)
  • Exhibit 16: Impact of drivers
  • Exhibit 17: Percentage of population diagnosed with migraine in US 2014
  • Exhibit 18: Impact of drivers and challenges
  • Exhibit 19: Allergan: YoY growth rate and revenue of Botox 2012-2014 ($ millions)
  • Exhibit 20: Allergan: Key takeaways
  • Exhibit 21: Endo International: Key takeaways
  • Exhibit 22: GlaxoSmithKline: YoY growth rate and revenue of Imigran/Imitrex 2012-2014 ($ millions)
  • Exhibit 23: GlaxoSmithKline: Key takeaways
  • Exhibit 24: Impax: YoY growth rate and revenue of Zomig in the US 2012-2014 ($ millions)
  • Exhibit 25: Impax: Key takeaways
  • Exhibit 26: Pfizer: YoY growth rate and revenue of Relpax 2012-2014 ($ millions)
  • Exhibit 27: Pfizer: Key takeaways
Back to Top